ネブラスカ州における片頭痛の臨床試験
ネブラスカ州内の拠点で、片頭痛に関する8件の研究が参加者を募集しています。
ネブラスカ州内の都市
公式研究テキスト（英語）
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
- Children's Hospital & Medical Center, Omaha
被験者募集中第1相
6歳〜11歳 · 全性別 · 2026/09/28更新 · NCT06995729Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
- Velocity Clinical Research, Grand Island, Grand Island
- Papillion Research Center/CCT Research, Papillion
被験者募集中第3相
6歳〜17歳 · 全性別 · 2026/09/28更新 · NCT05156398Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
- Children's Hospital & Medical Center, Omaha
被験者募集中第3相
6歳〜17歳 · 全性別 · 2026/09/24更新 · NCT04743141Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- Children's Hospital & Medical Center, Omaha
被験者募集中第3相
6歳〜17歳 · 全性別 · 2026/09/24更新 · NCT04649242A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
- Cct Research - Papillion Research Center /ID# 270393, Papillion
被験者募集中第3相
12歳〜17歳 · 全性別 · 2026/09/22更新 · NCT06810505Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- Nebraska Medical Center, Omaha
被験者募集中第4相
18歳〜70歳 · 全性別 · 2026/09/16更新 · NCT06972056Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
- Cognitive Clinical Trials (CCT) - Papillion /ID# 232552, Papillion
被験者募集中第3相
6歳〜17歳 · 全性別 · 2026/09/14更新 · NCT05125302Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks
- Tri City Research Center, LLC /ID# 278800, Grand Island
被験者募集中観察研究
18歳以上 · 全性別 · 2026/02/10更新 · NCT07310290ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。